Rao, Renata
 Distribuzione geografica
Continente #
NA - Nord America 308
EU - Europa 136
AS - Asia 105
Totale 549
Nazione #
US - Stati Uniti d'America 306
CN - Cina 43
IT - Italia 40
SG - Singapore 31
UA - Ucraina 23
DE - Germania 16
PL - Polonia 14
TR - Turchia 14
FI - Finlandia 13
GB - Regno Unito 13
HK - Hong Kong 10
IE - Irlanda 6
CZ - Repubblica Ceca 4
FR - Francia 4
CA - Canada 2
IN - India 2
IR - Iran 2
VN - Vietnam 2
AT - Austria 1
ID - Indonesia 1
RU - Federazione Russa 1
SE - Svezia 1
Totale 549
Città #
Fairfield 49
Ashburn 32
Singapore 24
Cambridge 22
Woodbridge 20
Chandler 19
Seattle 18
Houston 17
Jacksonville 17
Wilmington 15
Warsaw 14
Istanbul 13
Helsinki 10
Hong Kong 10
New York 10
Princeton 10
Dublin 6
Lancaster 6
Nanchang 6
Ann Arbor 5
Beijing 5
Nanjing 5
Cologno Monzese 4
Dearborn 4
Florence 4
Olomouc 4
Shanghai 4
Boardman 3
Brescia 3
Cascina 3
Cologno al Serio 3
Munich 3
Tianjin 3
Washington 3
Catania 2
Changsha 2
Dong Ket 2
Jiaxing 2
Jinan 2
Ningbo 2
Norwalk 2
San Francisco 2
Toronto 2
Verona 2
Ardabil 1
Augusta 1
Bergamo 1
Clifton 1
Cremona 1
Des Moines 1
Grafing 1
Guangzhou 1
Hebei 1
Jakarta 1
Kocaeli 1
London 1
Los Angeles 1
Milan 1
Morbegno 1
New Delhi 1
Presezzo 1
Romola 1
Rovato 1
Sabz 1
San Diego 1
Scafati 1
Shenyang 1
Taiyuan 1
Zhengzhou 1
Totale 419
Nome #
COVID-19 impact on consecutive neurological patients admitted to the emergency department 146
Where SUNCT Contacts TN: A Case Report 132
Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy 88
Un caso peculiare di ipertensione secondaria 70
Un caso peculiare di ipertensione arteriosa secondaria. 62
Increased risk of functional neurological disorders following SARS‐CoV‐2 vaccination 19
Post COVID-19 vaccination headache: A clinical and epidemiological evaluation 10
Photophobia and migraine outcome during treatment with galcanezumab 9
An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor 6
Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic Migraine 6
CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients 6
Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine 5
Migraine Disability and Severity Improvement during Long-Term Treatment with Erenumab 5
CGRP-monoclonal antibodies and SARS-CoV-2 vaccination 4
Totale 568
Categoria #
all - tutte 3.000
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.000


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202044 0 0 0 0 2 6 7 6 2 13 3 5
2020/2021169 4 6 3 7 51 44 3 11 11 13 9 7
2021/202254 2 19 0 0 0 2 4 2 4 4 6 11
2022/202362 5 4 1 3 5 11 0 12 13 2 2 4
2023/202475 4 1 10 5 1 19 0 1 12 1 13 8
2024/202592 8 0 4 62 18 0 0 0 0 0 0 0
Totale 568